SIGA Technologies

Executive Summary

SIGA Technologies is a commercial-stage biopharmaceutical company primarily focused on developing and commercializing TPOXX (tecovirimat), an FDA-approved antiviral for smallpox and other orthopoxviruses including monkeypox. The company derives a significant portion of its revenue from contracts with the U.S. government to supply TPOXX for the Strategic National Stockpile, providing a stable base. With a market cap of ~$375M and 11 pipeline candidates, SIGA is positioned to benefit from ongoing public health preparedness initiatives and potential label expansions. However, the termination of the Phase 3 mpox trial (NCT05534984) and reliance on government orders introduce risk. The active Phase 2 trial combining tecovirimat with a smallpox/mpox vaccine (NCT04957485) could expand its utility. Overall, SIGA occupies a unique niche in biodefense and emerging viral threats.

Upcoming Catalysts (preview)

• Q4 2026U.S. government contract renewal or expansion for TPOXX stockpiling80% success
• Q1 2026Data readout from Phase 2 trial of tecovirimat + smallpox/mpox vaccine (NCT04957485, expected completion Jan 2026)70% success
• Q2 2026Potential FDA approval for intravenous TPOXX formulation for severe orthopoxvirus infections60% success